TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05795504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistive exercise
Description: They will perform combined upper and lower resistive exercises, 30 min, 3 sessions / week for 12 weeks in addition to calcium and vitamin D supplements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval training
Description: They will perform HIIT for three sessions/ week for 12 weeks, 30 minutes/ session in addition to calcium and vitamin D supplements.,

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium and vitamin D
Description: they will receive calcium and vitamin D supplements only.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D
Description: they will receive calcium and vitamin D supplements only.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium and vitamin D
Description: they will receive calcium and vitamin D supplements only.
Study: NCT06082102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orelabrutinib Placebo
Description: Orelabrutinib Placebo Tablets
Study: NCT06562231

Intervention type: OTHER
Intervention: quality of life scale
Description: This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients.
Study: NCT05608642

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous hydration
Description: 500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous prednisolone
Description: The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine
Description: The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.
Study: NCT06604624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD1916
Description: HD1916，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: semaglutide
Description: semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Study: NCT06593522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 193
Description: Film-coated tablet
Study: NCT06575036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The starting dose of sugammadex will be 0.5mg/kg. When the dose for a patient was not effective, the dose for next patient will be increased by 0.5mg/kg. When the dose was effective, the dose for next patient will be decreased by 0.5mg/kg or maintained, with a 1:1 of allocation ratio.
Study: NCT05921630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient education before pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient education before pulmonary function test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient education before pulmonary function test
Study: NCT05456815

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized diet
Description: During 9 weeks all food products will be standardized and provided by the Research Unit. The standardized diet is based on the average food composition in the Netherlands.
Study: NCT06000085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: restoration of proximal cavities of primary molars with flowable giomer
Description: removal of proximal caries of primary molars and restoration of the cavities prepared by beautifil flow plus x

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restoration of proximal cavities of primary molars with highly viscous glass ionomer cement
Description: removal of proximal caries of primary molars and restoration of the cavities prepared by equia forte
Study: NCT04754984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor workshop
Description: Physiotherapist-led workshop on managing pelvic floor symptoms
Study: NCT05231603

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 0.4 mg/kg/day-maximum dose is 24 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to drug in term of tablets
Study: NCT05411276

Intervention type: DRUG
Intervention: Pyrotinib maleate
Description: Pyrotinib maleate tablets 400 mg/day, oral within 30 minutes after breakfast, every 4 weeks is a cycle
Study: NCT05811793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab and Bevacizumab
Description: Tislelizumab is a drug material authorized for marketing in China. Tislelizumab will be administered off-label in this study. Subjects with recurrent GBM will receive intrathecal tislelizumab every 3 weeks for six times. Intrathecal administration of Bevacizumab will be performed via Ommaya reservoir or intraventricular catheter.
Study: NCT05928247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT)
Description: During FCT, reinforcement will be discontinued for challenging behavior and only the alternative communication response will be reinforced. For participants with challenging behavior determined to be maintained by social-positive reinforcement (attention and/or tangible), the investigators also will typically recommend using a multiple schedule FCT (mult-FCT) to signal when reinforcement is available and to thin the schedule of reinforcement to render the treatment more practical for caregivers to implement. For participants with challenging behavior determined to be maintained by social-negative reinforcement (escape), the investigators will recommend using a chained schedule FCT (chained-FCT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Contingent Reinforcement (NCR)
Description: During NCR, the investigators will deliver the functional and competing reinforcers on time-based schedules and use multiple and chained schedules to signal when noncontingent reinforcement is available (similar to multiple- and chained-FCT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competing Items and Response Blocking
Description: The investigators will conduct a competing stimulus assessment (CSA) to identify items that produce at least an 80% reduction in challenging behavior when the participant is engaged with them. The investigators will evaluate conditions in which participants have free access to the item(s), when engagement with the item(s) is prompted, and when challenging behavior is physically blocked. Treatment will include one or more of the following components: non-contingent reinforcement informed by the CSA, reinforcing adaptive behavior, and blocking challenging behavior. The investigators will also use multiple and chained schedules to thin the reinforcement schedules and increase the practicality of the this treatment. The ending duration of the S-delta component will be based on input from caregivers and the participant's school personnel.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Units in Behavioral Intervention (RUBI) protocol
Description: Caregivers of participants with mild challenging behavior will receive training on a variety of topics, such as prevention strategies and functional communication training, throughout implementation of the RUBI protocol.
Study: NCT05133180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxervate
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle will be instilled with the same scheme of the test product
Study: NCT04790526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises Dose
Description: Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises Dose
Description: Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises Dose
Description: Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises Dose
Description: Eccentric exercise will be done treadmill in control environment. The treadmill will be declined to 16 degree and 3 sessions of 10 minutes duration will be given wit 1 minute of rest in each session. 10 minutes of warm up and cool down session will be given that includes stretching and stationary bicycle with out any resistance
Study: NCT06154083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin-delta (Rekovelle) 20 mcg/day from D1
Description: On day 2 or 3 of the menstrual cycle, daily injections of 20 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin-delta (Rekovelle) 15 mcg/day from D1
Description: On day 2 or 3 of the menstrual cycle, daily injections of 15 mcg of Rekovelle (Stimulation Day 1) will be administered. Scan controls and blood exams are performed on stimulation days 6, 8, 10 and, according to clinical needs, until trigger day. The dose will be the same during the whole course of stimulation and no dose adjustments will be performed.
Study: NCT05631964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion
Study: NCT06254807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-0525
Description: Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor
Study: NCT06087640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aQIV or aTIV
Description: Participants receive a 0.5-mL intramuscular dose of aQIV or aTIV on Day 1. A 0.5 mL dose of aQIV contains nominally 15 µg of hemagglutinin (HA) of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 µg HA). A 0.5 mL dose of aTIV contains nominally 15 µg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 µg HA). The strain composition of aQIV and aTIV is that recommended by the World Health Organization (WHO) for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: QIV or TIV
Description: Participants receive a 0.5-mL intramuscular dose of the non-adjuvanted QIV or TIV on Day 1. A 0.5 mL dose of QIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and each of the 2 influenza B strains (total of 60 μg HA). A 0.5 mL dose of TIV contains nominally 15 μg of HA of each of the 2 influenza type A strains and of the influenza B strain (total of 45 μg HA). The strain composition of QIV and TIV is that recommended by the WHO for quadrivalent and trivalent influenza vaccines, respectively, contemporaneous to the timing of the study.
Study: NCT05091437

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational study
Description: Incidental lung nodules identification

Intervention type: DIAGNOSTIC_TEST
Intervention: Observational study
Description: Incidental lung nodules identification
Study: NCT05245006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-YS5
Description: 3 mCi will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-YS5
Description: 3 mCi will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-YS5
Description: 3 mCi will be administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-YS5
Description: 3 mCi will be administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS5 antibody
Description: 20 or 50 mg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS5 antibody
Description: 20 or 50 mg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS5 antibody
Description: 20 or 50 mg administered intravenously

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Computerized tomography (CT)
Description: Imaging which combines a CT scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Computerized tomography (CT)
Description: Imaging which combines a CT scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Computerized tomography (CT)
Description: Imaging which combines a CT scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Computerized tomography (CT)
Description: Imaging which combines a CT scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Description: Imaging which combines an MRI scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Description: Imaging which combines an MRI scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Description: Imaging which combines an MRI scan and a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
Description: Imaging which combines an MRI scan and a PET scan
Study: NCT06353516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: delivered via intravenous route

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: delivered via inhalation route
Study: NCT05214950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI monitoring
Description: Oxygen reserve index monitoring during the surgery
Study: NCT04797728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elacestrant
Description: Elacestrant continuously at 400 mg given orally (PO), once a day, in a continuous schedule (QD) for 4 weeks (+/- 2 days)
Study: NCT05537857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary salt
Description: Controlled feeding study that varies in salt content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary salt
Description: Controlled feeding study that varies in salt content.
Study: NCT05280158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna COVID-19 vaccine)
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (Moderna COVID-19 vaccine)
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mRNA-1273 (Moderna COVID-19 vaccine)
Description: Study Drug will be administered via intramuscular injection (IM). Only one dose of study drug will be administered for the study.
Study: NCT05263882

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine combined with eribulin
Description: * Eribulin mesylate injection, specification: 2ml: 1mg/piece. Usage and dosage: 1.4mg/m2, intravenous bolus injection within 2-5 minutes, 21 days as a cycle, once on the 1st and 8th day of each cycle.~* Gemcitabine hydrochloride for injection, specification: 200mg: 1g/piece. Usage and dosage: administer gemcitabine (1000 mg/m2) intravenously over 30 minutes on the 1st and 8th day of every 21 days treatment cycle.~* The above combination regimen takes 21 days as a treatment cycle, and the efficacy is evaluated every 2 treatment cycles. The drug is continued until the disease progresses or intolerable adverse reactions occur.
Study: NCT04403737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rothman Index
Description: The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.
Study: NCT04787120

Intervention type: DEVICE
Intervention: SQUIDperi
Description: Liquid embolic delivery syringes and micro-catheter
Study: NCT05569824

Intervention type: DIAGNOSTIC_TEST
Intervention: Lateral-flow Device
Description: An additional amount of 0.1-0.2 ml (2-4 drops) of bronco-alveolar lavage (BAL) fluid will be collected during the bronchoscopy which is carried out as part of the standard of care. The LFD test will be carried out on the BAL fluid collected.
Study: NCT05189509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNK-Tissue Plasminogen Activator
Description: 0.25 mg TNK thrombolysis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TNK-Tissue Plasminogen Activator
Description: 0.25 mg TNK thrombolysis
Study: NCT04142814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-PEP
Description: First of all, a corrugated tube for ventilation is assembled: in one end with an antibacterial filter for ventilation and then an inflation system (like Auxiliary Manual Breathing Unit - AMBU); in the other end with a connector and then a one-way PEP Valve. The latter holds a junction for the tracheal cannula and a pressure gauge. A Venturi Resistor is placed in the expiratory part of the PEP Valve.~After connection to the tracheal cannula, the disostructive maneuver is manually executed by a respiratory physiotherapist.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPV
Description: IPV is delivered via a commercial device that can be set by frequency, duration of inspiratory time, inspiratory-expiratory ratio and positive end-expiratory pressure, based on patients characteristics and clinical needs. It is connected to the patient's tracheal cannula via a Mount catheter. The air supplied is sterile, due to the presence of an antibacterial filter present in the device.
Study: NCT05109377

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endocan
Description: Endocan will measured before and after treatment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Endocan
Description: Endocan will measured before and after treatment

Intervention type: DRUG
Group type: OTHER
Intervention: tadalafil
Description: tadalafil

Intervention type: DRUG
Group type: OTHER
Intervention: tadalafil
Description: tadalafil
Study: NCT04987554

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glycophosphopeptical AM3
Description: 3 g/day of AM3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 g/day of placebo
Study: NCT06470425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Participants receive supplement prescriptions from a physician based on current standard practices, which include biochemical markers, genetic data, and metabolic profiles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-Guided group
Description: Participants receive supplement prescriptions determined by GenAIS, is an AI system that considers genetic data, metabolic profiles, biochemical markers, and patient history.
Study: NCT06027983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric receptor T-cells + Trastuzumab
Description: Chimeric receptor T-cells will be administered by infusion. Trastuzumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine and Cyclophosphosphamide
Description: 3-day chemotherapy regimen of fludarabine and cyclophosphamide for lymphodepletion
Study: NCT06092502

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: The three different treatment techniques include left/right discrimination training, explicit motor imagery exercises and mirror therapy. These techniques are delivered sequentially but require a flexible approach from the patient and clinician to move forwards, backward and sideways in the treatment process to suit the individual. With patience, persistence and often lots of hard work, GMI gives new hope for treatment outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy Program
Description: This protocol included stretching and strengthening exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Physiotherapy Program
Description: This protocol included stretching and strengthening exercises
Study: NCT06600087

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Standardized self-administered questionnaire specifically designed for this study.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Standardized self-administered questionnaire specifically designed for this study.